J. Quinn Matuschek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Quinn Matuschek has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aaron W. Michels
Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, USA
1 shared publication - Ali H. Shilleh
Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
1 shared publication - Holger A. Russ
Diabetes Institute, University of Florida, Gainesville, FL 32610, USA
1 shared publication - Jessie M. Barra
University of Florida Diabetes Institute, University of Florida, Gainesville, FL, USA
1 shared publication - Kristen McDaniel
Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA
1 shared publication - Maria Skjøtt Hansen
Barbara Davis Center for Childhood Diabetes, University of Colorado, Anschutz Medical Campus 2 , Aurora, CO
1 shared publication
Latest Publications
- Open Access
Stem-Cell-Derived β-Like Cells with a Functional PTPN2 Knockout Display Increased Immunogenicity
Type 1 diabetes is a polygenic disease that results in an autoimmune response directed against insulin-producing beta cells. PTPN2 is a known high-risk type 1 diabetes associated gene expressed in both immune- and pancreatic beta cells, but how genes affect the development of autoimmune diabetes is largely unknown. We employed CRISPR/Cas9 technology to generate a functional knockout of PTPN2 in human pluripotent stem cells (hPSC) followed by differentiating stem-cell-derived beta-like cells (sBC) and detailed phenotypical analyses. The differentiation efficiency of PTPN2 knockout (PTPN2 KO) sBC is comparable to wild-type (WT) control sBC. Global transcriptomics and protein assays revealed the increased expression of HLA Class I molecules in PTPN2 KO sBC at a steady state and upon exposure to proinflammatory culture conditions, indicating a potential for the increased immune recognition of human beta cells upon differential PTPN2 expression. sBC co-culture with autoreactive preproinsulin-reactive T cell transductants confirmed increased immune stimulations by PTPN2 KO sBC compared to WT sBC. Taken together, our results suggest that the dysregulation of PTPN2 expression in human beta cell may prime autoimmune T cell reactivity and thereby contribute to the development of type 1 diabetes.
Open AccessStem-Cell-Derived β-Like Cells with a Functional PTPN2 Knockout Display Increased Immunogenicity
Type 1 diabetes is a polygenic disease that results in an autoimmune response directed against insulin-producing beta cells. PTPN2 is a known high-risk type 1 diabetes associated gene expressed in both immune- and pancreatic beta cells, but how genes affect the development of autoimmune diabetes is largely unknown. We employed CRISPR/Cas9 technology to generate a functional knockout of PTPN2 in human pluripotent stem cells (hPSC) followed by differentiating stem-cell-derived beta-like cells (sBC) and detailed phenotypical analyses. The differentiation efficiency of PTPN2 knockout (PTPN2 KO) sBC is comparable to wild-type (WT) control sBC. Global transcriptomics and protein assays revealed the increased expression of HLA Class I molecules in PTPN2 KO sBC at a steady state and upon exposure to proinflammatory culture conditions, indicating a potential for the increased immune recognition of human beta cells upon differential PTPN2 expression. sBC co-culture with autoreactive preproinsulin-reactive T cell transductants confirmed increased immune stimulations by PTPN2 KO sBC compared to WT sBC. Taken together, our results suggest that the dysregulation of PTPN2 expression in human beta cell may prime autoimmune T cell reactivity and thereby contribute to the development of type 1 diabetes.